CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites.
View/ Open
Date
2017-01-31Author
Sood, D
Johnson, N
Jain, P
Siskos, AP
Bennett, M
Gilham, C
Busana, MC
Peto, J
Dos-Santos-Silva, I
Keun, HC
Fletcher, O
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: Endogenous sex hormones are well-established risk factors for breast cancer; the contribution of specific oestrogen metabolites (EMs) and/or ratios of specific EMs is less clear. We have previously identified a CYP3A7*1C allele that is associated with lower urinary oestrone (E1) levels in premenopausal women. The purpose of this analysis was to determine whether this allele was associated with specific pathway EMs. METHODS: We measured successfully 12 EMs in mid-follicular phase urine samples from 30 CYP3A7*1C carriers and 30 non-carriers using HPLC-MS/MS. RESULTS: In addition to having lower urinary E1 levels, CYP3A7*1C carriers had significantly lower levels of four of the 2-hydroxylation pathway EMs that we measured (2-hydroxyestrone, P=1.1 × 10-12; 2-hydroxyestradiol, P=2.7 × 10-7; 2-methoxyestrone, P=1.9 × 10-12; and 2-methoxyestradiol, P=0.0009). By contrast, 16α-hydroxylation pathway EMs were slightly higher in carriers and significantly so for 17-epiestriol (P=0.002). CONCLUSIONS: The CYP3A7*1C allele is associated with a lower urinary E1 levels, a more pronounced reduction in 2-hydroxylation pathway EMs and a lower ratio of 2-hydroxylation:16α-hydroxylation EMs in premenopausal women. To further characterise the association between parent oestrogens, EMs and subsequent risk of breast cancer, characterisation of additional genetic variants that influence oestrogen metabolism and large prospective studies of a broad spectrum of EMs will be required.
Collections
Subject
Humans
Breast Neoplasms
Estrone
Estrogens
Risk Factors
Down-Regulation
Hydroxylation
Premenopause
Alleles
Adolescent
Adult
Middle Aged
Female
Cytochrome P-450 CYP3A
Metabolic Networks and Pathways
Young Adult
Genetic Carrier Screening
Research team
Functional Genetic Epidemiology
Language
eng
Date accepted
2016-12-01
License start date
2017-01-10
Citation
British journal of cancer, 2017, 116 (3), pp. 382 - 388
Publisher
NATURE PUBLISHING GROUP